Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation
Frontiers in pediatrics
; 10, 2022.
Article
in English
| EuropePMC | ID: covidwho-1998856
ABSTRACT
We present a case report of successful treatment with nirmatrelvir/ritonavir (Paxlvoid) for a severe aplastic anemia child with COVID-19, cytopenia, and mixed chimerism of donor hematopoietic cells at 3 months after allogeneic hematopoietic stem cell transplantation. After the 5-day entire course of treatment, the clinical symptoms were relieved, cycle threshold values of ORF1a/b and N genes increased from 22.60 and 22.15 to 34.52 and 33.84, respectively, and the peripheral blood counts gradually recovered without graft failure. Nirmatrelvir/ritonavir can effectively inhibit the replication of SARS-CoV-2 without any significant adverse effects.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Case report
Language:
English
Journal:
Frontiers in pediatrics
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS